Published in Aliment Pharmacol Ther on April 01, 2003
Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut (2007) 3.87
Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut (2012) 2.60
A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome. BMC Gastroenterol (2009) 1.60
Meta-analysis of probiotics for the treatment of irritable bowel syndrome. World J Gastroenterol (2008) 1.47
Bacterial probiotic modulation of dendritic cells. Infect Immun (2004) 1.35
Lower functional gastrointestinal disorders: evidence of abnormal colonic transit in a 287 patient cohort. Neurogastroenterol Motil (2009) 1.35
Inhibitory effects of Lactobacillus reuteri on visceral pain induced by colorectal distension in Sprague-Dawley rats. Gut (2005) 1.27
Irritable bowel syndrome, gut microbiota and probiotics. J Neurogastroenterol Motil (2011) 1.23
Probiotic Therapy of the Irritable Bowel Syndrome: Why Is the Evidence Still Poor and What Can Be Done About It? J Neurogastroenterol Motil (2015) 1.23
Probiotics and human health: a clinical perspective. Postgrad Med J (2004) 1.23
Systematic review: probiotics in the management of lower gastrointestinal symptoms in clinical practice -- an evidence-based international guide. Aliment Pharmacol Ther (2013) 1.21
Lactobacillus plantarum MB452 enhances the function of the intestinal barrier by increasing the expression levels of genes involved in tight junction formation. BMC Microbiol (2010) 1.20
Health benefits of probiotics: are mixtures more effective than single strains? Eur J Nutr (2011) 1.17
The role of a probiotics mixture in the treatment of childhood constipation: a pilot study. Nutr J (2007) 1.14
Challenges to the therapeutic pipeline for irritable bowel syndrome: end points and regulatory hurdles. Gastroenterology (2008) 1.14
Therapeutic effect of Lactobacillus acidophilus-SDC 2012, 2013 in patients with irritable bowel syndrome. Dig Dis Sci (2008) 1.11
Probiotics and medical nutrition therapy. Nutr Clin Care (2004) 1.10
The gut microbiota and irritable bowel syndrome: friend or foe? Int J Inflam (2012) 1.09
Use of probiotics in gastrointestinal disorders: what to recommend? Therap Adv Gastroenterol (2010) 0.99
Probiotic effects on intestinal fermentation patterns in patients with irritable bowel syndrome. World J Gastroenterol (2008) 0.99
Probiotics VSL#3 protect against development of visceral pain in murine model of irritable bowel syndrome. PLoS One (2013) 0.99
Are there any different effects of Bifidobacterium, Lactobacillus and Streptococcus on intestinal sensation, barrier function and intestinal immunity in PI-IBS mouse model? PLoS One (2014) 0.93
Effects of probiotic bacteria on gastrointestinal motility in guinea-pig isolated tissue. World J Gastroenterol (2006) 0.93
Effect of probiotics on symptoms in korean adults with irritable bowel syndrome. Gut Liver (2009) 0.92
Recommendations for probiotic use in humans-a 2014 update. Pharmaceuticals (Basel) (2014) 0.92
Probiotic therapy for irritable bowel syndrome. Gastroenterol Hepatol (N Y) (2010) 0.92
The effect of oral alpha-galactosidase on intestinal gas production and gas-related symptoms. Dig Dis Sci (2006) 0.92
Pathophysiology, evaluation, and treatment of bloating: hope, hype, or hot air? Gastroenterol Hepatol (N Y) (2011) 0.91
Modulation of intestinal microbiota by the probiotic VSL#3 resets brain gene expression and ameliorates the age-related deficit in LTP. PLoS One (2014) 0.90
Chronic bacterial prostatitis and irritable bowel syndrome: effectiveness of treatment with rifaximin followed by the probiotic VSL#3. Asian J Androl (2014) 0.89
New treatments for irritable bowel syndrome in women. Womens Health (Lond Engl) (2008) 0.88
Unraveling the ties between irritable bowel syndrome and intestinal microbiota. World J Gastroenterol (2014) 0.88
IBS--review and what's new. MedGenMed (2006) 0.87
Change of Fecal Flora and Effectiveness of the Short-term VSL#3 Probiotic Treatment in Patients With Functional Constipation. J Neurogastroenterol Motil (2015) 0.87
A randomised clinical trial (RCT) of a symbiotic mixture in patients with irritable bowel syndrome (IBS): effects on symptoms, colonic transit and quality of life. Int J Colorectal Dis (2012) 0.87
Diagnosis and treatment of diarrhea-predominant irritable bowel syndrome. Int J Gen Med (2016) 0.86
Gut microbiota role in irritable bowel syndrome: New therapeutic strategies. World J Gastroenterol (2016) 0.85
Gut microbiota is not modified by Randomized, Double-blind, Placebo-controlled Trial of VSL#3 in Diarrhea-predominant Irritable Bowel Syndrome. Probiotics Antimicrob Proteins (2011) 0.84
The treatment of irritable bowel syndrome. Therap Adv Gastroenterol (2009) 0.84
Probiotics. Some evidence of their effectiveness. Can Fam Physician (2005) 0.84
Effect of composite yogurt enriched with acacia fiber and Bifidobacterium lactis. World J Gastroenterol (2012) 0.84
Therapeutic effects of biobran, modified arabinoxylan rice bran, in improving symptoms of diarrhea predominant or mixed type irritable bowel syndrome: a pilot, randomized controlled study. Evid Based Complement Alternat Med (2014) 0.83
New onset of constipation during long-term physical inactivity: a proof-of-concept study on the immobility-induced bowel changes. PLoS One (2013) 0.83
Actual concept of "probiotics": is it more functional to science or business? World J Gastroenterol (2013) 0.82
The human microbiome and probiotics: implications for pediatrics. Curr Probl Pediatr Adolesc Health Care (2008) 0.82
Probiotic products in Canada with clinical evidence: what can gastroenterologists recommend? Can J Gastroenterol (2008) 0.81
The interplay of the gut microbiome, bile acids, and volatile organic compounds. Gastroenterol Res Pract (2015) 0.81
Probiotics, prebiotics and the gastrointestinal tract in health and disease. Inflammopharmacology (2014) 0.81
Food allergy in irritable bowel syndrome: new facts and old fallacies. Gut (2004) 0.81
The efficacy of a synbiotic containing Bacillus Coagulans in treatment of irritable bowel syndrome: a randomized placebo-controlled trial. Gastroenterol Hepatol Bed Bench (2014) 0.80
A review of the pharmacobiotic regulation of gastrointestinal inflammation by probiotics, commensal bacteria and prebiotics. Inflammopharmacology (2012) 0.80
Effect of korean herbal medicine combined with a probiotic mixture on diarrhea-dominant irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial. Evid Based Complement Alternat Med (2013) 0.80
Selected interventions in nuclear medicine: gastrointestinal motor functions. Semin Nucl Med (2009) 0.80
Abdominal bloating and distension: what is the role of the microbiota. Dig Dis Sci (2011) 0.80
A pilot study on the effect of a symbiotic mixture in irritable bowel syndrome: an open-label, partially controlled, 6-month extension of a previously published trial. Tech Coloproctol (2013) 0.79
Small Intestinal Bacterial Overgrowth and Irritable Bowel Syndrome: A Bridge between Functional Organic Dichotomy. Gut Liver (2017) 0.79
Modulation of microbiota as treatment for intestinal inflammatory disorders: An uptodate. World J Gastroenterol (2016) 0.78
Do probiotics improve symptoms in patients with irritable bowel syndrome? Therap Adv Gastroenterol (2009) 0.78
Pharmacodynamic and clinical endpoints for functional colonic disorders: statistical considerations. Dig Dis Sci (2012) 0.78
Colon-targeted delivery of live bacterial cell biotherapeutics including microencapsulated live bacterial cells. Biologics (2008) 0.78
Fecal excretion of Bifidobacterium infantis 35624 and changes in fecal microbiota after eight weeks of oral supplementation with encapsulated probiotic. Gut Microbes (2013) 0.77
Vitamin D associates with improved quality of life in participants with irritable bowel syndrome: outcomes from a pilot trial. BMJ Open Gastroenterol (2015) 0.77
Molecular characterization of the intestinal microbiota in patients with and without abdominal bloating. Am J Physiol Gastrointest Liver Physiol (2015) 0.76
Clinical Uses of Probiotics. Medicine (Baltimore) (2016) 0.76
The effects of multi-strain probiotic compound on symptoms and quality-of-life in patients with irritable bowel syndrome: A randomized placebo-controlled trial. Adv Biomed Res (2014) 0.76
Management Strategies for Abdominal Bloating and Distension. Gastroenterol Hepatol (N Y) (2014) 0.76
Efficacy of probiotics and nutrients in functional gastrointestinal disorders: a preliminary clinical trial. Dig Dis Sci (2006) 0.76
Effect of herbal extract granules combined with probiotic mixture on irritable bowel syndrome with diarrhea: study protocol for a randomized controlled trial. Trials (2011) 0.76
The Emerging Therapeutic Role of Medical Foods for Gastrointestinal Disorders. Gastroenterol Hepatol (N Y) (2017) 0.76
Therapeutic Modulation of Gut Microbiota in Functional Bowel Disorders. J Neurogastroenterol Motil (2017) 0.75
Alpha-galactosidase versus active charcoal for improving sonographic visualization of abdominal organs in patients with excessive intestinal gas. J Ultrasound (2012) 0.75
Gas and Bloating. Gastroenterol Hepatol (N Y) (2006) 0.75
Common Functional Gastroenterological Disorders Associated With Abdominal Pain. Mayo Clin Proc (2016) 0.75
Influence of E. coli strain Nissle 1917 (EcN) on intestinal gas dynamics and abdominal sensation. Dig Dis Sci (2007) 0.75
Probiotic for irritable bowel syndrome in pediatric patients: a randomized controlled clinical trial. Electron Physician (2015) 0.75
Probiotics and irritable bowel syndrome. Microb Ecol Health Dis (2012) 0.75
Efficacy of double-coated probiotics for irritable bowel syndrome: a randomized double-blind controlled trial. J Gastroenterol (2016) 0.75
The Induction of Oxalate Metabolism In Vivo Is More Effective with Functional Microbial Communities than with Functional Microbial Species. mSystems (2017) 0.75
Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology (1997) 8.51
A clinical trial of a chest-pain observation unit for patients with unstable angina. Chest Pain Evaluation in the Emergency Room (CHEER) Investigators. N Engl J Med (1998) 5.67
Dyspepsia and dyspepsia subgroups: a population-based study. Gastroenterology (1992) 4.84
Eosinophilic gastroenteritis: a clinicopathological study of patients with disease of the mucosa, muscle layer, and subserosal tissues. Gut (1990) 4.60
Simplified assessment of segmental colonic transit. Gastroenterology (1987) 4.59
Crohn's disease in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. Gastroenterology (1998) 4.52
Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction. Gastroenterology (1993) 4.23
Percutaneous endoscopic gastrostomy. Indications, success, complications, and mortality in 314 consecutive patients. Gastroenterology (1987) 4.19
Surgical management of Meckel's diverticulum. An epidemiologic, population-based study. Ann Surg (1994) 4.16
A 21-year experience with major hemorrhage after percutaneous liver biopsy. Gastroenterology (1990) 4.02
Epidemiology of colonic symptoms and the irritable bowel syndrome. Gastroenterology (1991) 3.90
Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology (2001) 3.85
Prevalence of columnar-lined (Barrett's) esophagus. Comparison of population-based clinical and autopsy findings. Gastroenterology (1990) 3.77
The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology (2001) 3.60
A patient questionnaire to identify bowel disease. Ann Intern Med (1989) 3.43
Assessment of functional gastrointestinal disease: the bowel disease questionnaire. Mayo Clin Proc (1990) 3.34
A new questionnaire for gastroesophageal reflux disease. Mayo Clin Proc (1994) 3.14
Anterior temporal lobes and hippocampal formations: normative volumetric measurements from MR images in young adults. Radiology (1989) 3.12
Lack of discriminant value of dyspepsia subgroups in patients referred for upper endoscopy. Gastroenterology (1993) 2.99
Risk factors for irritable bowel syndrome: role of analgesics and food sensitivities. Am J Gastroenterol (2000) 2.89
Ulcerative colitis in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. Gut (2000) 2.86
Medical costs in community subjects with irritable bowel syndrome. Gastroenterology (1995) 2.81
Risk factors associated with symptoms of gastroesophageal reflux. Am J Med (1999) 2.75
Irritable bowel syndrome: a technical review for practice guideline development. Gastroenterology (1997) 2.71
Temporal lobe seizures: lateralization with MR volume measurements of the hippocampal formation. Radiology (1990) 2.56
Onset and disappearance of gastrointestinal symptoms and functional gastrointestinal disorders. Am J Epidemiol (1992) 2.54
Chronic idiopathic intestinal pseudo-obstruction: clinical and intestinal manometric findings. Gut (1987) 2.46
Performance characteristics of scintigraphic transit measurements for studies of experimental therapies. Aliment Pharmacol Ther (2002) 2.37
Gastric adenocarcinoma and Helicobacter pylori infection. J Natl Cancer Inst (1991) 2.35
Sex differences in evaluation and outcome of unstable angina. JAMA (2000) 2.33
Assessment of gastric accommodation: overview and evaluation of current methods. Neurogastroenterol Motil (2004) 2.28
A comparison of the Rome and Manning criteria for case identification in epidemiological investigations of irritable bowel syndrome. Am J Gastroenterol (2000) 2.27
Fine-needle aspiration biopsy of thyroid nodules. Impact on thyroid practice and cost of care. Am J Med (1982) 2.23
Definition and investigation of dyspepsia. Consensus of an international ad hoc working party. Dig Dis Sci (1989) 2.23
PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut (2005) 2.22
Prevalence of gastrointestinal symptoms in the elderly: a population-based study. Gastroenterology (1992) 2.17
Effect of colesevelam on faecal bile acids and bowel functions in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther (2015) 2.13
Gastrointestinal tract symptoms and self-reported abuse: a population-based study. Gastroenterology (1994) 2.12
Validating biomarkers of treatable mechanisms in irritable bowel syndrome. Neurogastroenterol Motil (2014) 2.11
Relation among personality and symptoms in nonulcer dyspepsia and the irritable bowel syndrome. Gastroenterology (1990) 2.09
Severe exercise-induced ischemia does not identify high risk patients with normal left ventricular function and one- or two-vessel coronary artery disease. J Am Coll Cardiol (1994) 2.08
Clinical predictors of recurrent Clostridium difficile infection in out-patients. Aliment Pharmacol Ther (2014) 2.08
Secular trends in the epidemiology and outcome of Barrett's oesophagus in Olmsted County, Minnesota. Gut (2001) 2.05
Indium 111-granulocyte scanning in the assessment of disease extent and disease activity in inflammatory bowel disease. A comparison with colonoscopy, histology, and fecal indium 111-granulocyte excretion. Gastroenterology (1986) 2.03
Constipation in an elderly community: a study of prevalence and potential risk factors. Am J Gastroenterol (1996) 2.01
Self-reported abuse and gastrointestinal disease in outpatients: association with irritable bowel-type symptoms. Am J Gastroenterol (1995) 1.99
Mechanisms of hypersensitivity in IBS and functional disorders. Neurogastroenterol Motil (2007) 1.98
Enteric neuronal autoantibodies in pseudoobstruction with small-cell lung carcinoma. Gastroenterology (1991) 1.98
Irritable bowel syndrome in a community: symptom subgroups, risk factors, and health care utilization. Am J Epidemiol (1995) 1.94
Predictors of outcome after percutaneous endoscopic gastrostomy: a community-based study. Mayo Clin Proc (1992) 1.94
Serotonin: a mediator of the brain-gut connection. Am J Gastroenterol (2000) 1.93
Lipoprotein analysis in the evaluation of chest pain in the emergency department. Mayo Clin Proc (1991) 1.92
Transit of solids through the human colon: regional quantification in the unprepared bowel. Am J Physiol (1990) 1.90
Effects of an irritable bowel syndrome educational class on health-promoting behaviors and symptoms. Am J Gastroenterol (1998) 1.88
Is there a role for gastric accommodation and satiety in asymptomatic obese people? Obes Res (2001) 1.84
MR imaging-based volume measurements of the hippocampal formation and anterior temporal lobe: validation studies. Radiology (1990) 1.84
Epidemiologic aspects of Crohn's disease: a population based study in Olmsted County, Minnesota, 1943-1982. Gut (1988) 1.82
Nonsteroidal antiinflammatory drugs and dyspepsia in the elderly. Dig Dis Sci (1995) 1.81
Relation between antral motility and gastric emptying of solids and liquids in humans. Am J Physiol (1985) 1.81
Effect of growth hormone, glutamine, and diet on adaptation in short-bowel syndrome: a randomized, controlled study. Gastroenterology (1997) 1.80
Relationship between impaired gastric emptying and abnormal gastrointestinal motility. Gastroenterology (1986) 1.79
Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders. Aliment Pharmacol Ther (2012) 1.79
Quality of life after proctocolectomy. A comparison of Brooke ileostomy, Kock pouch, and ileal pouch-anal anastomosis. Gastroenterology (1991) 1.77
Towards a less costly but accurate test of gastric emptying and small bowel transit. Dig Dis Sci (1991) 1.76
Functional constipation and outlet delay: a population-based study. Gastroenterology (1993) 1.74
Recombinant human neurotrophic factors accelerate colonic transit and relieve constipation in humans. Gastroenterology (2000) 1.74
Human gastric emptying and colonic filling of solids characterized by a new method. Am J Physiol (1989) 1.73
Performance characteristics of scintigraphic colon transit measurement in health and irritable bowel syndrome and relationship to bowel functions. Neurogastroenterol Motil (2009) 1.73
Evaluation of gastrointestinal transit in clinical practice: position paper of the American and European Neurogastroenterology and Motility Societies. Neurogastroenterol Motil (2011) 1.72
Risk of lymphoma in inflammatory bowel disease. Am J Gastroenterol (2000) 1.71
Increasing incidence of pancreatic cancer among women in Olmsted County, Minnesota, 1940 through 1988. Mayo Clin Proc (1992) 1.69
Patients with asymptomatic primary sclerosing cholangitis frequently have progressive disease. Gastroenterology (1990) 1.69
Clinical predictors of small intestinal bacterial overgrowth by duodenal aspirate culture. Aliment Pharmacol Ther (2011) 1.68
Diagnostic value of the Manning criteria in irritable bowel syndrome. Gut (1990) 1.68
Relationship between symptoms and disordered continence mechanisms in women with idiopathic faecal incontinence. Gut (2005) 1.67
Chronic ulcerative colitis: incidence and prevalence in a community. Gut (1987) 1.66
Antibiotic prophylaxis for percutaneous endoscopic gastrostomy. A prospective, randomized, double-blind clinical trial. Ann Intern Med (1987) 1.65
Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder. Gastroenterology (2001) 1.64
Modulation of collagen gene expression by cytokines: stimulatory effect of transforming growth factor-beta1, with divergent effects of epidermal growth factor and tumor necrosis factor-alpha on collagen type I and collagen type IV. J Lab Clin Med (1997) 1.64
Familial association in adults with functional gastrointestinal disorders. Mayo Clin Proc (2000) 1.64
Scintigraphic measurement of regional gut transit in idiopathic constipation. Gastroenterology (1991) 1.63
Human enteric neuropathies: morphology and molecular pathology. Neurogastroenterol Motil (2004) 1.63
Gastrointestinal tract symptoms among persons with diabetes mellitus in the community. Arch Intern Med (2000) 1.61